MedTrace Logo

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

NCT00523380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-03-01

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of rIL-21 and Caelyx in cancer patients who have relapsed after, or have persistent disease after, first line therapy. Patients will be treated for 6 months.

Conditions

Interventions

DRUG

recombinant interleukin-21

Administered i.v. in treatment cycles of 28 days.

DRUG

caelyx (pegylated liposomal doxorubicin)

Administered i.v. in treatment cycles of 28 days.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-04
Primary Completion
2009-01-07
Completion
2009-01-07

Countries

  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00523380 on ClinicalTrials.gov